[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Johnson & Johnson Medical (Shanghai) Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100555293","the-study-is-an-observational-post-market-follow-up-program-to-evaluate-long-term-5-years-safety-of-mentor-breast-implants-in-chinese-population-100555293",false,"NCT06510205","The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety of Mentor Breast Implants in Chinese Population","MNT202401: Post Market Clinical Follow up for Mentor Breast Implants","Inclusion Criteria:\n\n1. Women who have received Mentor breast implants per product instructions;\n2. Participants must possess the ability to comprehend the study procedures, give consent for the use of their preoperative and surgical data, and agree to take part in postoperative follow-up assessments. Additionally, they should possess the necessary civil capacity, be capable of reading and writing, and willingly provide informed consent by signing the consent form.\n3. Aged not less than 18 years at the time of implantation surgery (for products with registration license Guoxie Zhujin 20223130323, the participant's age should be not less than 22 years).\n\nExclusion Criteria:\n\n* Not applicable","FEMALE","18 Years","100 Years",{"count":20,"type":21},6111,"ESTIMATED","OBSERVATIONAL","The Mentor Post-Market Clinical Follow-Up Study is a multicenter observational study conducted in China. It aims to collect safety data on Mentor breast implants over a 5-year follow-up period in the Chinese population. In addition to safety data, the study will also gather information on postoperative pain and participant satisfaction levels. The objective is to explore customers' clinical experiences and use them as a reference for future product development. The study intends to enroll different number of participants for each license.",[25,26],"Breast Augmentation","Mammaplasty","RECRUITING","2026-06-11",{"date":30,"type":31},"2026-06-15","ACTUAL",{"date":33,"type":31},"2024-07-14",{"date":35,"type":21},"2034-12-31",{"name":37,"class":38},"Johnson & Johnson Medical (Shanghai) Ltd.","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100632244","a-study-of-varipulse-catheter-in-participants-with-paroxysmal-atrial-fibrillation-under-optimized-sedation-100632244","NCT07511166","A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation","High-quality Pulmonary Veins Isolation Using Varipulse Catheter Under Contact and Continuity Guidance in Patients With Paroxysmal Atrial Fibrillation Under Optimized Sedation","GreatPFA","Inclusion criteria:\n\n* Diagnosed with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF) or intolerable to class I and\u002For III antiarrhythmic drugs (AAD) based on medical records\n* Age 18-80 years\n* Able and willing to comply with all pre-procedure, post-procedure, and follow-up testing and visit requirements\n* Signed patient informed consent form (ICF)\n\nExclusion criteria:\n\n* Atrial fibrillation (AF) secondary to electrolyte imbalance, hyperthyroidism, or reversible or non-cardiac cause\n* Previous left atrium (LA) ablation or surgery\n* Left atrium diameter (LAD) greater than (\\>) 50 millimeters (mm) by transthoracic echocardiography (TTE)\n* Left ventricular ejection fraction (LVEF) less than (\\\u003C) 40 percent (%)\n* Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study\n* Current enrollment in an investigational study evaluating another device or drug\n* Women who are pregnant (as evidenced by pregnancy test or oral confirmation if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation\n* Life expectancy less than 12 months\n* Presenting contra-indications for the devices used in the study, as indicated in the respective instructions for use (IFU)\n* Presenting contra-indications for catheter ablation at physicians' discretion, for example LA\u002FLeft atrial appendage (LAA) thrombus, systematic infection, situations preventing catheter access\n* Other conditions that, at discretion of the investigators, would preclude enrollment in this study","ALL","80 Years",{"count":50,"type":21},300,"The main purpose of the study is to assess how well the standard ablation procedure (Varipulse Catheter) works over long term when used with different types of anesthesia in participants with symptomatic paroxysmal atrial fibrillation (PAF, irregular heartbeat that comes and goes on its own, causing noticeable symptoms like a racing heart, or shortness of breath).",[53],"Atrial Fibrillation","NOT_YET_RECRUITING","2026-06-04",{"date":57,"type":31},"2026-06-05",{"date":59,"type":21},"2026-07-01",{"date":61,"type":21},"2028-03-28",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100610494","a-study-of-choydar-flow-directed-mesh-stent-in-the-treatment-of-unruptured-intracranial-aneurysms-100610494","NCT07228312","A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms","A Multicenter, Prospective, Single-Arm Observational Study to Evaluate the Safety and Effectiveness of the Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms","CROWN","Inclusion criteria:\n\nParticipants meeting all the following inclusion criteria will be included:\n\nPreoperative inclusion criteria:\n\n* Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA) prior to surgery, wide-neck (neck width greater than or equal to \\[\\>=\\] 4 millimeters \\[mm\\] or dome-to-neck ratio less than \\[\\\u003C\\] 2) saccular or fusiform aneurysms, and the parent artery diameter must be \\>= 2.0 mm and less than or equal to \\[\\\u003C=\\] 6.0 mm\n* Participants and\u002For their authorized representatives understand the purpose of the study, and are willing to voluntarily participate in the study and sign the informed consent form (ICF)\n* Prior to enrollment, a clinical decision has already been made to use the choydar flow-directed mesh stent\n* Participants who are willing and able to return for all follow-up visits as required by the study protocol\n\nIntraoperative inclusion criteria:\n\n\\- Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by DSA during the procedure, wide-neck (neck width \\>= 4 mm or dome-to-neck ratio \\\u003C2) saccular or fusiform aneurysms, and the parent artery diameter must be \\>= 2.0 mm and \\\u003C= 6.0 mm\n\nExclusion criteria:\n\nParticipants meeting any of the following exclusion criteria will be excluded:\n\n* Participants with anatomy are unsuitable for flow diverter passage or placement or lesions unsuitable for flow diverter delivery and deployment (for example, the lesion vessel is excessively tortuous or tiny, the flow diverter cannot reach the lesion site, stenosis exists in the target vessel of recurrent aneurysm, or the flow diverter is not completely deployed)\n* Participants who are allergic to contrast media\n* Participants who are allergic to nickel-titanium alloy or platinum-tungsten alloy\n* Participants who are contraindicated for antiplatelet and\u002For anticoagulant therapy\n* Participants with active bacterial infections\n* Participants who are confirmed positive pregnancy (for example, via test or oral communication) according to the site-specific standard of care\n* Participants who are currently participating in an investigational (drug, device, etc.) clinical study that may confound the study endpoints (excluding observational, natural history, and\u002For epidemiological studies that do not require interventions)",{"count":72,"type":21},200,"The purpose of this study is to assess how safe choydar flow-directed mesh stent is and how well it works in the treatment of unruptured intracranial aneurysms (a condition in which a bulging blood vessel in the brain can burst and cause bleeding) in a real-world setting.",[75],"Intracranial Aneurysm",{"date":57,"type":31},{"date":78,"type":31},"2026-01-28",{"date":80,"type":21},"2028-02-10",{"name":37,"class":38},""]